Intra-Cellular raises $150M as it preps schizophrenia drug filing by Phil Taylor Tuesday, October 3, 2017 Intra-Cellular Therapies raised its target of $150 million, which will help it prepare for an FDA filing for lumateperone in schizophrenia next year.
Biotech IPOs; CHMP knockbacks—News of Note by Ben Adams Friday, July 21, 2017 Check out Friday's dose of biotech's news of note.
Alkermes is advancing 'full steam' with schizophrenia drug by Phil Taylor Friday, June 30, 2017 Alkermes has cleared the first major hurdle in its bid to advance schizophrenia candidate ALKS 3831, showing an improvement over placebo in its first phase 3 trial—but a much bigger test is still to come.
